Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Limited growth in generics will lead to moves for innovative drugs, Prasad says.
You may also be interested in...
Dr. Reddy's CEO Dodges GSK Equity Deal Rumors - PharmAsia Summit
SAN FRANCISCO - Emotions should not come in the way of promoters wanting to sell their businesses, said Dr. Reddy's Labs Vice Chairman G.V. Prasad, while eluding questions pointed at a widely speculated equity deal between his company and GlaxoSmithKline
Dr. Reddy's To Close Atlanta Facility In Reorganization; Focus On Key Markets To Drive Revenues To $3 Billion By 2013
MUMBAI - Need for optimization of infrastructure and resources, falling productivity and spiraling cost of discovery research has led Dr. Reddy's Labs, one of India's largest drug companies, to integrate its drug discovery operations with Aurigene - a partnership-based discovery biotech unit that it owns in Bangalore
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.